Nwm 16 sept programme

What does Cambridge offer the Biologics and Biosimilars Future?

16 September 2015

Deloitte, City House, 126 – 130 Hills Road, Cambridge CB2 1RY

Programme 17.30

18.00

Registration Welcome from Host, Jenny Hopkins, Deloitte Landscape of Academic and Industrial R&D in Biologics in Cambridge: A One Nucleus Report Albert Perez-Riba, One Nucleus

18.30

Panel Discussion: What does Cambridge offer the Biologics and Biosimilars Future?

Chair - Tony Jones, One Nucleus Jim Huntington, University of Cambridge and Founder XO1 Albert Perez-Riba, One Nucleus Andreas Arnell, Lonza Biologics Steve Dowd, Kymab

19.30

20.30

Networking over drinks and canapĂŠs

Event closes

Speaker Profiles Andreas Arnell Lead Scientist, Lonza Andreas is a Lead Scientist in Bioinformatics at Lonza’s Applied Protein Services department.

His work focusses on pre-clinical risk assessment and risk mitigation of biotherapeutics by analysing immunogenicity, stability and aggregation propensity. During his 8-years as a protein engineer at Lonza, his experiences include antibody humanisation, deimmunisation, Fc-fusions, scFv’s, ADC’s, focussed library design and linker design.

Andreas has an MSc in Bioengineering from Chalmers University of Technology, Gothenburg, Sweden.

Jenny Hopkins Manager, Deloitte Jenny is a Manager in our Corporate Tax practice, working with a wide range of businesses from start-ups to listed entities. Over the past four years she has specialised in working with private organisations on both compliance and advisory issues, particularly focussing on R&D tax credits and, more recently, restructurings.

Jenny has a wide range of experience advising companies in our health and life sciences practice including Heptares, Pulmagen, Creabilis, and e-Therapeutics.

Jim Huntington Professor of Molecular Haemostasis, Cambridge Institute for Medical Research and Entrepreneur

Jim Huntington graduated in 1989 from the University of Kansas with bachelor’s degrees in chemistry and mathematics. While an undergraduate, he worked as a research assistant in the Pharmaceutical Chemistry Department and at the Merck subsidiary InterX under Takeru Higuchi, Ooi Wong and Jose Alexander. His research focussed on chemical synthesis and testing of prodrugs and prodrug-like enhancers of skin permeability. After graduating, he was employed as a chemist at Alza Corporation in California for three years evaluating compounds that enhanced the electrotransport of drugs across the skin. He obtained a PhD from Vanderbilt University in 1997 for work on the biophysical characterisation of members of the serpin family of proteins with Peter Gettins. His research on the serpins continued during his postdoc with Robin Carrell at the University of Cambridge, where he used X-ray crystallography to determine the mechanisms of serpin function. He was appointed principal investigator at the Cambridge Institute for Medical Research in 1999, University Reader in 2007 and Professor in 2011. His research focuses on serpin function and dysfunction, and on the regulation of blood coagulation. He has founded four biotech companies, including XO1 (recently acquired by Janssen Pharmaceuticals), Serpin Haemostatics, Z Factor and Cambridge Protein Works.

Speaker Profiles Albert Perez-Riba Intern, One Nucleus

Dominic is a partner at Bristows LLP, specialising in patent litigation. His practice focuses on the life sciences, reflecting his technical background (PhD Zoology, University of Cambridge).

Dominic has extensive experience of cross-border litigation in and beyond Europe and has worked on all aspects of the pharmaceutical product life cycle, from freedom to operate analyses and early-stage risk assessment of generic competition to end-stage litigation, SPCs and anti-trust issues.

Dominic writes regularly on reported patent cases in the UK and at the EPO and is a member of the AIPPI. He is a regular conference speaker and presenter.

Steve Dowd Director, Business Development, Kymab Steve has worked in the biotechnology and pharmaceutical industry for over 15 years in both commercial and research positions. His current role involves forming strategic partnerships with pharmaceutical and biotechnology companies, as well as academic institutions, to maximise the application of Kymab’s antibody discovery and development capability and build our pipeline of therapeutic products.

Previously, Steve has held research leadership roles over a long career in big pharma with GlaxoSmithKline and SmithKline Beecham.

Steve has a PhD from his work at Imperial Cancer Research Fund (now Cancer Research UK) and an MBA from the University of Cambridge Judge Business School.

Specialities: Business Development, Drug Discovery and Development , Strategic Consulting, Strategic Planning & Execution, Commercial Analysis, People Management, Project Management, Due Diligence , Target Validation and Multiple Therapeutic Area Expertise.

Delegate List First name Richard Andreas Luca Mike Bristi Tarquin Tom Emilie Ray Iphigenie Helen Deborah Yuehua Julian Jayne Greer Bobby Stephen Tim Jenny Sarah Jim Tony Pradyp Andrew Simon Jim James Alicja Tom Adam Dror Rina Antonio Stuart Albert Martyn Graham Sahar Nadia

Surname Anderson Arnell Badiali Bannister Basu Bennett-Coles Bradley Braun Chan Charatsi Chard Cockerill Cong Cooper Curry Deal Deal Dowd Gamble Hopkins Howell Huntington Jones Kanabar Kenyon King Kinnier Wilson Legg Malysiak Mander Michael Nir Nir Parada Penney Perez-Riba Postle Roberts Shepperd Shivji

Company Sciad Communications Ltd Lonza Biologics Plc Arecor Limited Europa Bioproducts Ltd University of Cambridge Euromedica Executive Search Ltd Euromedica Executive Search Ltd SANOFI Abcam plc Public Health England PiR Limited Sciad Communications Ltd F-star Biotechnology Ltd Illingworth Research Limited Arecor Limited Global Regulatory Services Global Regulatory Services Kymab Limited SCRIP Intelligence Deloitte Arecor Limited Cambridge Institute for Medical Research (CIMR) One Nucleus Bio-Analytical Technologies (UK) Limited BioClone Ltd. Remtec Search & Selection Ltd Penningtons Manches LLP Crescendo Biologics Selvita Ltd. Domainex Ltd 80th Atom RadBee Ltd RadBee Ltd Fairjourney Biologics Euromedica Executive Search Ltd One Nucleus Cambridge Healthcare and Biotech Ltd Ispire Motivational Coaching Bristows LLP One Nucleus

Matthew Yvette Daniela Saroj Parthiban Edward

Sleeman Stallwood Teixeira Velamakanni Vijayarangakannan Walker

Andrew Nigel Alan Tim

Walsh Whittle Williams Worden

MedImmune Limited Lonza Biologics Plc Fairjourney Biologics Fahy Gurteen Laboratories Cambridgene Miti Biosystems Cambridge Enterprise Limited University of Cambridge 14M Genomics Managing Resources Ltd Taylor Wessing